The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global antihypertensive drugs market exhibited XX growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of XX% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different XX. These insights are included in the report as a major market contributor.
Antihypertensive drugs are therapeutic medications used for preventing, controlling and treating hypertension and high blood pressure disorders. Hypertension is the prolonged and persistent elevation in blood pressure, which can lead to cardiac stroke and aneurism. Some commonly used antihypertensive drugs include diuretics, beta-blockers, calcium channel blockers, angiotensin-converting enzyme (ACE) inhibitors and vasodilators. These drugs remove excess fluids and salts from the body and relax and widen the blood vessels. They also aid in slowing down the heartbeat and maintaining a healthy systolic blood pressure. These drugs can be administered orally or through intravenous injections and are widely used in hospitals, clinics, rehabilitation centers and ambulatory surgical centers.
The increasing prevalence of hypertension and cardiovascular disorders across the globe is one of the key factors driving the growth of the market. Moreover, the rising geriatric population, which is more susceptible to such ailments, is anticipated to drive the market toward growth. Due to the increasingly sedentary lifestyles and adoption of unhealthy dietary patterns, there is an alarming increase in the number of patients suffering from high blood pressure and hypertension. This has led to the widespread adoption of antihypertensive drugs for timely prevention and treatment of hypertension. In line with this, the widespread adoption of combination therapies is contributing to the growth of the market. These innovative therapies combine multiple drugs to treat several hypertensive mechanisms, resulting in reduced occurrence of cerebrovascular events and coronary issues. Additionally, the development of imidazolines, monatepil and neutral endopeptidase inhibitors are acting as other growth-inducing factors. These next-generation drugs cause minimal fatigue and dry mouth and can also aid in lowering blood pressure by inhibiting the metabolism of vasoactive peptides. Other factors, including rising healthcare expenditures of the consumers, along with extensive research and development (R&D) activities, are anticipated to drive the market toward growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global antihypertensive drugs market report, along with forecasts for growth at the global, regional and country level from 2021-2026. Our report has categorized the market based on therapeutic class, type and distribution channel.
Breakup by Therapeutic Class:
Breakup by Type:
Breakup by Distribution Channel:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being AstraZeneca, Boehringer Ingelheim International GmbH., Daiichi Sankyo Company Limited, Johnson & Johnson Services Inc., Lupin Pharmaceuticals Inc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi and Sun Pharmaceutical Industries Ltd.
|Base Year of the Analysis||2020|
|Segment Coverage||Therapeutic Class, Type, Distribution Channel, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||AstraZeneca, Boehringer Ingelheim International GmbH., Daiichi Sankyo Company Limited, Johnson & Johnson Services Inc., Lupin Pharmaceuticals Inc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi and Sun Pharmaceutical Industries Ltd.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at